BRPI0518242A2 - mÉtodos terapÊuticos e de liberaÇço de agonistas de prostaglandina ep4 - Google Patents
mÉtodos terapÊuticos e de liberaÇço de agonistas de prostaglandina ep4Info
- Publication number
- BRPI0518242A2 BRPI0518242A2 BRPI0518242-5A BRPI0518242A BRPI0518242A2 BR PI0518242 A2 BRPI0518242 A2 BR PI0518242A2 BR PI0518242 A BRPI0518242 A BR PI0518242A BR PI0518242 A2 BRPI0518242 A2 BR PI0518242A2
- Authority
- BR
- Brazil
- Prior art keywords
- prostaglandin
- agonists
- therapeutic
- prodrug
- release methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62242204P | 2004-10-26 | 2004-10-26 | |
| PCT/US2005/038303 WO2006047476A2 (en) | 2004-10-26 | 2005-10-24 | Therapeutic and delivery methods of prostaglandin ep4 agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0518242A2 true BRPI0518242A2 (pt) | 2008-11-11 |
Family
ID=35840538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0518242-5A BRPI0518242A2 (pt) | 2004-10-26 | 2005-10-24 | mÉtodos terapÊuticos e de liberaÇço de agonistas de prostaglandina ep4 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080132543A1 (https=) |
| EP (1) | EP1805139A2 (https=) |
| JP (1) | JP2008518013A (https=) |
| AU (1) | AU2005299473B2 (https=) |
| BR (1) | BRPI0518242A2 (https=) |
| CA (1) | CA2585367A1 (https=) |
| WO (1) | WO2006047476A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006052893A2 (en) * | 2004-11-08 | 2006-05-18 | Allergan, Inc. | Substituted pyrrolidone compounds as ep4 agonists |
| US20060281818A1 (en) * | 2005-03-21 | 2006-12-14 | Sucampo Ag, North Carolina State University | Method for treating mucosal disorders |
| US20070232660A1 (en) * | 2006-04-04 | 2007-10-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
| EP2120962A1 (en) * | 2006-12-18 | 2009-11-25 | Allergan, Inc. | Methods and compositions for treating gastrointestinal disorders |
| EP2408444A4 (en) | 2009-03-19 | 2012-09-26 | Fate Therapeutics Inc | COMPOSITIONS WITH CYCLIC AMP AMPLIFIERS AND / OR EP LIGANDS, AND METHOD FOR THEIR PRODUCTION AND USE |
| WO2011047048A1 (en) | 2009-10-14 | 2011-04-21 | Gemmus Pharma, Inc. | Combination therapy treatment for viral infections |
| EP2603227B1 (en) | 2010-08-12 | 2017-10-04 | Fate Therapeutics, Inc. | Improved hematopoietic stem and progenitor cell therapy |
| AU2011364973A1 (en) * | 2011-04-07 | 2013-11-07 | Allergan, Inc. | Devices, compositions and methods utilizing EP4 and EP2 receptor agonists for preventing, reducing or treating capsular contracture |
| PT2760994T (pt) | 2011-09-30 | 2017-08-24 | Bluebird Bio Inc | Compostos para melhor transdução viral |
| US10111907B2 (en) | 2011-12-02 | 2018-10-30 | Fate Therapeutics, Inc. | Methods of treating ischemia |
| EP3785767A1 (en) | 2011-12-02 | 2021-03-03 | Fate Therapeutics, Inc. | Enhanced stem cell composition |
| US10851412B2 (en) | 2013-03-15 | 2020-12-01 | Fate Therapeutics, Inc. | Cell potency assay for therapeutic potential |
| US9943545B2 (en) | 2013-03-15 | 2018-04-17 | Fate Therapeutics, Inc. | Stem cell culture media and methods of enhancing cell survival |
| KR102456567B1 (ko) | 2013-08-09 | 2022-10-19 | 알데릭스, 인코포레이티드 | 인산염 수송을 억제하기 위한 화합물 및 방법 |
| WO2017139561A1 (en) | 2016-02-12 | 2017-08-17 | Bluebird Bio, Inc. | Vcn enhancer compositions and methods of using the same |
| WO2017139576A1 (en) | 2016-02-12 | 2017-08-17 | Bluebird Bio, Inc. | Vcn enhancer compositions and methods of using the same |
| WO2020237096A1 (en) | 2019-05-21 | 2020-11-26 | Ardelyx, Inc. | Combination for lowering serum phosphate in a patient |
| GB202211232D0 (en) | 2022-08-02 | 2022-09-14 | Heptares Therapeutics Ltd | Prostaglandin EP4 receptor agonist compounds |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5714346B2 (https=) * | 1973-07-12 | 1982-03-24 | ||
| KR880012221A (ko) * | 1987-04-13 | 1988-11-26 | 사노 가즈오 | 에스테르 또는 아미드를 활성성분으로 함유하는 약제 조성물 |
| US6043275A (en) * | 1998-04-16 | 2000-03-28 | Ono Pharmaceutical Co., Ltd. | 3,7-dithiaprostanoic acid derivative |
| TWI249520B (en) * | 1998-07-15 | 2006-02-21 | Ono Pharmaceutical Co | 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient |
| KR20010074981A (ko) * | 1998-09-14 | 2001-08-09 | 우에노 도시오 | ω치환된 페닐프로스타그란딘 Ｅ 유도체 및 그 유도체를유효 성분으로 하는 약제 |
| US20020002140A1 (en) * | 2000-01-14 | 2002-01-03 | Holick Michael F. | Novel bisphosphonates and uses thereof |
| OA12533A (en) * | 2000-11-27 | 2006-06-05 | Pfizer Prod Inc | Ep4 receptor selective agonists in the treatment of osteoporosis. |
| US20050222094A1 (en) * | 2001-06-14 | 2005-10-06 | Burk Robert M | Treatment of inflammatory bowel disease |
| US20030027853A1 (en) * | 2001-06-14 | 2003-02-06 | Allergan Sales, Inc. | 3, 7or3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure |
| CA2451392A1 (en) * | 2001-07-16 | 2003-01-30 | F. Hoffmann-La Roche Ag | Prostaglandin analogues as ep4 receptor agonists |
| EP2255829A3 (en) * | 2001-07-23 | 2012-03-28 | Ono Pharmaceutical Co., Ltd. | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient |
| WO2003077910A1 (en) * | 2002-03-18 | 2003-09-25 | Pfizer Products Inc. | Methods of treatment with selective ep4 receptor agonists |
| US7053085B2 (en) * | 2003-03-26 | 2006-05-30 | Merck & Co. Inc. | EP4 receptor agonist, compositions and methods thereof |
| CA2511255C (en) * | 2003-01-10 | 2009-04-07 | F. Hoffmann-La Roche Ag | 2-piperidone derivatives as prostaglandin agonists |
| US6875787B2 (en) * | 2003-02-11 | 2005-04-05 | Allergan, Inc. | 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure |
| AU2004211936B2 (en) * | 2003-02-11 | 2008-09-11 | Allergan, Inc. | 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure |
-
2005
- 2005-10-24 AU AU2005299473A patent/AU2005299473B2/en not_active Ceased
- 2005-10-24 EP EP05817142A patent/EP1805139A2/en not_active Withdrawn
- 2005-10-24 CA CA002585367A patent/CA2585367A1/en not_active Abandoned
- 2005-10-24 BR BRPI0518242-5A patent/BRPI0518242A2/pt not_active Application Discontinuation
- 2005-10-24 WO PCT/US2005/038303 patent/WO2006047476A2/en not_active Ceased
- 2005-10-24 US US11/574,528 patent/US20080132543A1/en not_active Abandoned
- 2005-10-24 JP JP2007539030A patent/JP2008518013A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006047476A2 (en) | 2006-05-04 |
| AU2005299473A1 (en) | 2006-05-04 |
| WO2006047476A3 (en) | 2006-09-28 |
| CA2585367A1 (en) | 2006-05-04 |
| US20080132543A1 (en) | 2008-06-05 |
| JP2008518013A (ja) | 2008-05-29 |
| EP1805139A2 (en) | 2007-07-11 |
| AU2005299473B2 (en) | 2012-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0518242A2 (pt) | mÉtodos terapÊuticos e de liberaÇço de agonistas de prostaglandina ep4 | |
| JP5198063B2 (ja) | 新規バイオ開裂性リンカー | |
| NO20091620L (no) | Boronsyre og estere som inhibitorer av fettsyreamidhydrolaser | |
| MY139577A (en) | Anti-inflammatory androstane derivative | |
| MX2011012627A (es) | Derivados aminobutiricos sustituidos como inhibidores de nepralisina. | |
| ECSP109905A (es) | Moduladores de receptor 7 tipo toll | |
| EA200801165A1 (ru) | Антагонисты неосновного рецептора-1 меланинконцентрирующего гормона | |
| PT2323972E (pt) | Compostos de tetraciclina substituídos com c7-flúor | |
| WO2003099338A3 (en) | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues | |
| MX2011007737A (es) | Derivados de hidroximetil isoxazol como moduladores de acido gamma-aminobutirico a. | |
| JP2948658B2 (ja) | 新規アミノ酸誘導体、その製造方法およびその医薬組成物 | |
| AR048973A1 (es) | (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)amida del acido 4-hidroxi-4-metil-piperidin-1-carboxilico. proceso de preparacion y composiciones farmaceuticas | |
| AU2007341218B2 (en) | Isosorbide mononitrate derivatives for the treatment of intestinal disorders | |
| UA122762C2 (uk) | Пероральна композиція 9-[(2,2-диметилпропіламіно)-метил]-міноцикліну або його солі, тверда пресована дозована форма, композиція для ін'єкцій, застосування та спосіб приготування фармацевтичної композиції | |
| MX2025000635A (es) | Compuestos cíclicos y métodos de utilización de estos | |
| WO2006043655A1 (ja) | 吸入用医薬組成物 | |
| BR0311642A (pt) | Formulação de divalproex de sódio de liberação aumentada | |
| EP2155736A4 (en) | NEW CARBAMOYLOXYARYL ALKANOYLARYLPIPERAZIN COMPOUND, PHARMACEUTICAL COMPOSITIONS CONTAINING THE COMPOUND, AND METHOD FOR TREATING PAIN, FEAR AND DEPRESSION BY PROVIDING THE COMPOUND | |
| PH12022551248A1 (en) | 1,2,4-oxadiazole derivatives as liver x receptor agonists | |
| BRPI0506493A (pt) | combinações terapêuticas | |
| NZ599268A (en) | Pharmaceutical compositions of rhein or diacerein made by wet granulation process | |
| JP6402110B2 (ja) | アミノペプチダーゼｎおよびネプリライシンの混合阻害剤 | |
| US12577211B2 (en) | Probenecid compounds for the treatment of inflammasome-mediated lung disease | |
| AR050043A1 (es) | Metodos para mejorar la biodisponibilidad y composicion farmaceutica para trastornos cardiovasculares | |
| WO2022234447A1 (en) | Nlrp3 inflammasome-inhibiting compounds and the use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B15K | Others concerning applications: alteration of classification |
Ipc: C07C 405/00 (2006.01), A61K 47/54 (2017.01), A61K |
|
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |